{"id":"W2965796930","doi":"10.1016/j.jaci.2019.07.013","title":"Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis","year":2019,"lang":"en","type":"article","venue":"Journal of Allergy and Clinical Immunology","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":false,"ca_institutions":"Innovaderm (Canada)","funders":"Janssen Biotech; MedImmune; Glenmark Pharmaceuticals; Galderma; AstraZeneca; Asana Biosciences; Dermira; AbbVie; UCB; Celgene; Regeneron Pharmaceuticals; Novartis; Pfizer","keywords":"Syk; Atopic dermatitis; Janus kinase; Skin barrier; Inflammation; Filaggrin; Medicine; Janus; Dermatology; Immunology; Tyrosine kinase; Internal medicine; Cytokine; Receptor; Materials science; Nanotechnology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001956975,0.0002739091,0.0005803201,0.0001386282,0.0001700925,0.000215199,0.0001619967,0.0001856584,0.001395332],"category_scores_gemma":[0.0001808535,0.00008348036,0.0003509858,0.0001388775,0.0001314588,0.0001926706,0.0001132641,0.0006258693,0.0002269187],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001020765,"about_ca_system_score_gemma":0.0002046967,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002513497,"about_ca_topic_score_gemma":0.0007314922,"domain_scores_codex":[0.999929,0.00001953555,0.000009114997,0.000008865515,0.00001517458,0.00001846843],"domain_scores_gemma":[0.9999354,0.00001287981,0.00001402318,0.000005687695,0.000006018183,0.0000260189],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1009192,0.01704019,0.03776,0.001611014,0.0008894341,0.002303837,0.0001911321,0.0006672373,0.4436084,0.0003114372,0.004588344,0.3901098],"study_design_scores_gemma":[0.04242714,0.1596268,0.5852318,0.0003288613,0.003375021,0.01040191,0.001069312,0.006817932,0.1658948,0.0009550552,0.02376479,0.0001066096],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9944847,0.00391796,0.0001820278,0.0001328936,0.00006955775,0.00002864607,0.00007147397,0.00004066786,0.001072027],"genre_scores_gemma":[0.9974548,0.001307612,0.0002330223,0.0001121779,0.00004071626,0.00002069011,0.0001305455,0.000003496908,0.0006969428],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001395332,"threshold_uncertainty_score":0.004667878,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007561517437909385,"score_gpt":0.2594861952114428,"score_spread":0.2519246777735334,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}